• Doheny Annual CME Conference

    Doheny Eye Institute 150 North Orange Grove Blvd. Rm 264, Pasadena, CA, United States

    Please join us for a half-day conference that will feature presentations covering a range of ophthalmic topics presented by Doheny alumni, Doheny and Stein faculty, and Dr. Van Gelder in areas of clinical practice, research, and diagnostic advances for improved patient care.

  • Annual Alumni Dinner Honoring Mark Borchert, MD

    Doheny Eye Institute 150 North Orange Grove Blvd. Rm 264, Pasadena, CA, United States

    All friends, colleagues, family, and alumni are invited to celebrate this year’s honoree, Mark S. Borchert, MD, of CHLA. Each year the Doheny Professional Association honors a member as the “Distinguished Alumnus” for achievement and commitment to the advancement of ophthalmic research, education, or patient care. The annual dinner is immediately following the conference. RSVPs can be made at doheny.org/alumni23.

  • Doheny-UCLA Breakfast Forum at ARVO

    New Orleans Marriott Warehouse Arts District 859 Convention Center Boulevard, New Orleans, LA, United States

    This year's theme is Accelerating Discovery of Disease Mechanism: High-Resolution Imaging Links Structure to Function. The seminar will feature internationally recognized leaders in developing and using advanced retinal imaging. They will cover the latest developments in adaptive optics imaging, optical coherence tomography, and fluorescence lifetime imaging ophthalmoscopy.

  • Annual Doheny-UCLA Stein Reception at ARVO

    Le Meridien New Orleans 333 Poydras Street, New Orleans, LA, United States

    We hope you will join us on Monday, April 24, 2023 to reconnect with friends and colleagues at our annual reception held during the ARVO meeting. This year ARVO will take place in New Orleans, LA, from Sunday, April 23 – Wed, April 26

  • Doheny-UCLA Breakfast Forum at ARVO 2024

    Grand Hyatt Seattle, Menzies Suite, 6th Floor 721 Pine St, Seattle, WA, United States

    Fresh Perspectives on Retinopathy Retinopathy remains the leading cause of vision loss in the global working population. Regardless of whether it is triggered by ischemia or diabetes, the late vision-threatening stage of retinopathy is marked by VEGF-mediated pathological neovascularization and concomitant vascular leakage. As such, anti-VEGF therapies have long been the preferred strategy to manage […]